Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio

Fineline Cube Jul 17, 2026
Company Drug

Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma

Fineline Cube Jul 17, 2026
Company Deals

Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization

Fineline Cube Sep 12, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...

Company Deals

Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy

Fineline Cube Sep 12, 2024

Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on...

Policy / Regulatory

China Aims to Fortify Insurance Industry by 2035 with New State Council Directives

Fineline Cube Sep 12, 2024

The State Council has issued the “Several Opinions on Strengthening Supervision, Preventing Risks, and Promoting...

Company Drug

Suzhou GenAssist Launches First-of-Its-Kind Base Editing Drug Trial for Duchenne Muscular Dystrophy

Fineline Cube Sep 12, 2024

Suzhou GenAssist Therapeutic Co., Ltd, a biopharmaceutical company based in China, has announced the commencement...

Company Medical Device

Siemens Healthineers’ 7T MRI System Terra. X Receives NMPA Marketing Approval

Fineline Cube Sep 12, 2024

Siemens Healthineers AG has secured marketing approval from China’s National Medical Products Administration (NMPA) for...

Company Drug

Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting

Fineline Cube Sep 12, 2024

Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...

Company Deals

CSA Medical Inc. Secures USD 53 Million in Series D Financing to Advance Cryotherapy Treatment

Fineline Cube Sep 11, 2024

CSA Medical Inc., a U.S.-based medical technology company, has successfully closed a Series D financing...

Company

Celltrion Inc. Enters CDMO Arena Amid Shifts in Global Biosecurity Landscape

Fineline Cube Sep 11, 2024

South Korea’s biosimilars giant, Celltrion Inc., is gearing up to expand into the contract development...

Company Deals

Gilead Sciences Partners with AI Firm Genesis Therapeutics to Develop Novel Small-Molecule Therapies

Fineline Cube Sep 11, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company based in the U.S., has entered into...

Company Deals

Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies

Fineline Cube Sep 11, 2024

Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage...

Company Deals

Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector

Fineline Cube Sep 11, 2024

Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Shows Promising Results in Phase II Study for ALK+ NSCLC

Fineline Cube Sep 11, 2024

Qilu Pharmaceutical, a leading pharmaceutical company based in China, has presented updated results from the...

Company Deals

ImmuneOnco Receives Second Payment from Instil Bio, Highlighting Ongoing Licensing Deal

Fineline Cube Sep 11, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the receipt of a further payment...

Company Drug

Nuance Pharma Completes Enrollment for Phase III COPD Trial of Ohtuvayre in China

Fineline Cube Sep 11, 2024

Nuance Pharma, a China-based pharmaceutical company, has announced the completion of patient enrollment for the...

Company Drug

Innovent Biologics Presents Promising Phase I Data for IBI363 in Advanced NSCLC at WCLC

Fineline Cube Sep 11, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has unveiled Phase...

Company Drug

Betta Pharmaceuticals’ MCLA129 for Advanced Solid Tumors Accepted for Review by China’s NMPA

Fineline Cube Sep 11, 2024

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a pharmaceutical company based in China, has announced that...

Company Drug

Duality Biologics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors

Fineline Cube Sep 11, 2024

Duality Biologics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with...

Company Medical Device

Medtronic Secures China Market Approval for Pulsed Electric Field Atrial Fibrillation Treatment Devices

Fineline Cube Sep 11, 2024

Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approvals...

Company Drug Legal / IP

AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute

Fineline Cube Sep 11, 2024

AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...

Company Drug

Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss Results in Phase I Trial

Fineline Cube Sep 10, 2024

Terns Pharmaceuticals Inc. (NASDAQ: TERN), a U.S.-based biotechnology company originally spun out from Eli Lilly’s...

Posts pagination

1 … 329 330 331 … 696

Recent updates

  • Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
  • Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
  • Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma
  • Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression
  • Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation

Company Drug

Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio

Company Drug

Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.